Peringatan Keamanan

Side effects include abdominal pain, amnesia, dizziness, drowsiness, eye pain, headache, memory loss, menstrual pain, nausea, sleepiness, tingling, weakness

Zaleplon

DB00962

small molecule approved illicit investigational

Deskripsi

Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States.

Struktur Molekul 2D

Berat 305.3339
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Approximately 1 hour
Volume Distribusi * 1.4 L/kg
Klirens (Clearance) * 1 L/h/kg

Absorpsi

Absorption Zaleplon is rapidly and almost completely absorbed following oral administration.

Metabolisme

Zaleplon is primarily metabolized by aldehyde oxidase.

Rute Eliminasi

Zaleplon is metabolized primarily by the liver and undergoes significant presystemic metabolism. After oral administration, zaleplon is extensively metabolized, with less than 1% of the dose excreted unchanged in urine. Renal excretion of unchanged zaleplon accounts for less than 1% of the administered dose.

Interaksi Makanan

2 Data
  • 1. Avoid alcohol. Ingesting alcohol may increase the CNS depressant effects of zaleplon.
  • 2. Do not take with or immediately after a high-fat meal. The effects of zaleplon are reduced when taken with a high-fat meal.

Interaksi Obat

1622 Data
Buprenorphine Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.
Hydrocodone Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.
Magnesium sulfate The therapeutic efficacy of Zaleplon can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Zaleplon may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.
Mirtazapine Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.
Orphenadrine Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.
Pramipexole Zaleplon may increase the sedative activities of Pramipexole.
Ropinirole Zaleplon may increase the sedative activities of Ropinirole.
Rotigotine Zaleplon may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Zaleplon.
Suvorexant Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.
Thalidomide Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Mefloquine The therapeutic efficacy of Zaleplon can be decreased when used in combination with Mefloquine.
Mianserin The therapeutic efficacy of Zaleplon can be decreased when used in combination with Mianserin.
Orlistat Orlistat can cause a decrease in the absorption of Zaleplon resulting in a reduced serum concentration and potentially a decrease in efficacy.
Topotecan Zaleplon may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Zaleplon.
Flumazenil Flumazenil may decrease the sedative activities of Zaleplon.
Sodium oxybate Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Cimetidine The metabolism of Zaleplon can be decreased when combined with Cimetidine.
Tetracosactide The risk or severity of liver damage can be increased when Tetracosactide is combined with Zaleplon.
Ethanol Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.
Fluvoxamine The risk or severity of adverse effects can be increased when Zaleplon is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Zaleplon is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Zaleplon is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Zaleplon is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Zaleplon is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Zaleplon is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Zaleplon is combined with Sibutramine.
Escitalopram The risk or severity of adverse effects can be increased when Zaleplon is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Zaleplon is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Zaleplon is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Zaleplon is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Zaleplon is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Zaleplon is combined with Seproxetine.
Levomilnacipran Zaleplon may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Indalpine The risk or severity of adverse effects can be increased when Zaleplon is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Zaleplon is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Zaleplon is combined with Alaproclate.
Benzatropine Benzatropine may decrease the excretion rate of Zaleplon which could result in a higher serum level.
Disopyramide Disopyramide may decrease the excretion rate of Zaleplon which could result in a higher serum level.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Zaleplon.
Amoxapine The risk or severity of CNS depression can be increased when Amoxapine is combined with Zaleplon.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Zaleplon.
Propantheline Propantheline may decrease the excretion rate of Zaleplon which could result in a higher serum level.
Dicyclomine Dicyclomine may decrease the excretion rate of Zaleplon which could result in a higher serum level.
Cocaine The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Cocaine.
Maprotiline The risk or severity of CNS depression can be increased when Maprotiline is combined with Zaleplon.
Tolterodine Zaleplon may decrease the excretion rate of Tolterodine which could result in a higher serum level.
Flavoxate Zaleplon may decrease the excretion rate of Flavoxate which could result in a higher serum level.
Tiotropium Zaleplon may decrease the excretion rate of Tiotropium which could result in a higher serum level.
Pizotifen The risk or severity of CNS depression can be increased when Zaleplon is combined with Pizotifen.
Fesoterodine Zaleplon may decrease the excretion rate of Fesoterodine which could result in a higher serum level.
Aclidinium Zaleplon may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Trimebutine Zaleplon may decrease the excretion rate of Trimebutine which could result in a higher serum level.
Dosulepin The risk or severity of CNS depression can be increased when Zaleplon is combined with Dosulepin.
Imidafenacin Zaleplon may decrease the excretion rate of Imidafenacin which could result in a higher serum level.
Propiverine Zaleplon may decrease the excretion rate of Propiverine which could result in a higher serum level.
Oxybutynin The metabolism of Oxybutynin can be decreased when combined with Zaleplon.
Quetiapine The risk or severity of CNS depression can be increased when Zaleplon is combined with Quetiapine.
Nicardipine The metabolism of Zaleplon can be decreased when combined with Nicardipine.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Zaleplon.
Imipramine The risk or severity of CNS depression can be increased when Imipramine is combined with Zaleplon.
Doxepin The risk or severity of CNS depression can be increased when Zaleplon is combined with Doxepin.
Nortriptyline The risk or severity of CNS depression can be increased when Nortriptyline is combined with Zaleplon.
Desipramine The risk or severity of CNS depression can be increased when Zaleplon is combined with Desipramine.
Zopiclone The risk or severity of adverse effects can be increased when Zaleplon is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Zaleplon.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Zaleplon.
Tryptophan The risk or severity of CNS depression can be increased when Tryptophan is combined with Zaleplon.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.
Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Zaleplon.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Zaleplon.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Zaleplon.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Zaleplon.
Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Zaleplon.
Reboxetine The risk or severity of CNS depression can be increased when Reboxetine is combined with Zaleplon.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Zaleplon.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Zaleplon.
Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Zaleplon.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Zaleplon.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Zaleplon.
Venlafaxine The risk or severity of CNS depression can be increased when Venlafaxine is combined with Zaleplon.
Etomidate The risk or severity of CNS depression can be increased when Etomidate is combined with Zaleplon.
Morphine The risk or severity of CNS depression can be increased when Morphine is combined with Zaleplon.
Talbutal The risk or severity of CNS depression can be increased when Talbutal is combined with Zaleplon.
Valproic acid The risk or severity of CNS depression can be increased when Valproic acid is combined with Zaleplon.

Target Protein

Gamma-aminobutyric acid receptor subunit alpha-1 GABRA1

Referensi & Sumber

Synthesis reference: Farhan Aslam, "Polymorphs of zaleplon and methods for the preparation thereof." U.S. Patent US20020072527, issued June 13, 2002.
Artikel (PubMed)
  • PMID: 15252823
    Dundar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T: Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol. 2004 Jul;19(5):305-22.
  • PMID: 15037809
    Noguchi H, Kitazumi K, Mori M, Shiba T: Electroencephalographic properties of zaleplon, a non-benzodiazepine sedative/hypnotic, in rats. J Pharmacol Sci. 2004 Mar;94(3):246-51.
  • PMID: 17853625
    Ramakrishnan K, Scheid DC: Treatment options for insomnia. Am Fam Physician. 2007 Aug 15;76(4):517-26.
  • PMID: 15783240
    Barbera J, Shapiro C: Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Saf. 2005;28(4):301-18.
  • PMID: 10983740
    Dooley M, Plosker GL: Zaleplon: a review of its use in the treatment of insomnia. Drugs. 2000 Aug;60(2):413-45.
  • PMID: 10804040
    Holm KJ, Goa KL: Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs. 2000 Apr;59(4):865-89.
  • PMID: 12404558
    Patat A, Paty I, Hindmarch I: Pharmacodynamic profile of Zaleplon, a new non-benzodiazepine hypnotic agent. Hum Psychopharmacol. 2001 Jul;16(5):369-392.

Contoh Produk & Brand

Produk: 78 • International brands: 1
Produk
  • Sonata
    Capsule • 5 mg/1 • Oral • US • Approved
  • Sonata
    Capsule • 10 mg/1 • Oral • US • Approved
  • Sonata
    Capsule • 5 mg/1 • Oral • US • Approved
  • Sonata
    Capsule • 10 mg/1 • Oral • US • Approved
  • Sonata
    Capsule • 5 mg • Oral • EU
  • Sonata
    Capsule • 5 mg • Oral • EU
  • Sonata
    Capsule • 5 mg • Oral • EU
  • Sonata
    Capsule • 10 mg • Oral • EU
Menampilkan 8 dari 78 produk.
International Brands
  • Zalaplon

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul